Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Increased permeability of psoriatic skin to the protein, plasminogen activator inhibitor 2.

Gould AR, Sharp PJ, Smith DR, Stegink AJ, Chase CJ, Kovacs JC, Penglis S, Chatterton BE, Bunn CL.

Arch Dermatol Res. 2003 Nov;295(6):249-54. Epub 2003 Sep 9.

PMID:
13680270
2.

Effect of finite doses of propylene glycol on enhancement of in vitro percutaneous permeation of loperamide hydrochloride.

Trottet L, Merly C, Mirza M, Hadgraft J, Davis AF.

Int J Pharm. 2004 Apr 15;274(1-2):213-9.

PMID:
15072797
3.

Doxorubicin skin penetration from monoolein-containing propylene glycol formulations.

Herai H, Gratieri T, Thomazine JA, Bentley MV, Lopez RF.

Int J Pharm. 2007 Feb 1;329(1-2):88-93. Epub 2006 Aug 24.

PMID:
17027205
4.

Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin.

Johansen C, Kragballe K, Rasmussen M, Dam TN, Iversen L.

Br J Dermatol. 2004 Sep;151(3):600-7.

PMID:
15377346
5.

In vivo study of skin mechanical properties in psoriasis vulgaris.

Dobrev H.

Acta Derm Venereol. 2000 Jul-Aug;80(4):263-6.

PMID:
11028858
6.
7.

Correlation of epidermal plasminogen activator activity with disease activity in psoriasis.

Fraki JE, Lazarus GS, Gilgor RS, Marchase P, Singer KH.

Br J Dermatol. 1983 Jan;108(1):39-44.

PMID:
6336944
8.
9.

Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes.

Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK.

J Control Release. 2007 Nov 6;123(2):148-54. Epub 2007 Aug 16.

PMID:
17884226
10.

The effects of calcipotriol and methylprednisolone aseponate on bcl-2, p53 and ki-67 expression in psoriasis.

Adişen E, Gülekon A, Erdem O, Dursun A, Gürer MA.

J Eur Acad Dermatol Venereol. 2006 May;20(5):527-33.

PMID:
16684279
11.
12.

In vivo quantification of microvessels in clinically uninvolved psoriatic skin and in normal skin.

Hern S, Mortimer PS.

Br J Dermatol. 2007 Jun;156(6):1224-9. Epub 2007 Apr 25.

PMID:
17459047
13.

Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.

Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJ, Greenfield RS.

Int J Mol Med. 2007 Nov;20(5):683-7.

PMID:
17912461
14.

Expression of Bcl-2 family proteins in psoriasis.

Batinac T, Zamolo G, Hadzisejdić I, Zauhar G, Brumini G, Ruzić A, Persić V.

Croat Med J. 2007 Jun;48(3):319-26.

15.

Studying the effectiveness of penetration enhancers to deliver retinol through the stratum cornum by in vivo confocal Raman spectroscopy.

Mélot M, Pudney PD, Williamson AM, Caspers PJ, Van Der Pol A, Puppels GJ.

J Control Release. 2009 Aug 19;138(1):32-9. doi: 10.1016/j.jconrel.2009.04.023. Epub 2009 May 4.

PMID:
19401210
16.
17.
18.

The release and percutaneous permeation of anthralin products, using clinically involved and uninvolved psoriatic skin.

Wang JC, Patel BG, Ehmann CW, Lowe N.

J Am Acad Dermatol. 1987 Apr;16(4):812-21.

PMID:
3571544
19.

Effect of vehicles and enhancers on the topical delivery of cyclosporin A.

Liu H, Li S, Wang Y, Yao H, Zhang Y.

Int J Pharm. 2006 Mar 27;311(1-2):182-6. Epub 2006 Jan 24.

PMID:
16439077
20.

Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy.

Coolman M, de Groot CJ, Steegers EA, Geurts-Moespot A, Thomas CM, Steegers-Theunissen RP, Sweep FC.

Eur J Obstet Gynecol Reprod Biol. 2006 Sep-Oct;128(1-2):22-8. Epub 2006 Apr 11.

PMID:
16584829
Items per page

Supplemental Content

Write to the Help Desk